Compounds which: (a) bind to a 5-HT1A receptor with an affinity of at least 10-7M, (b) bind to a 5-HT¿1A? receptor with an affinity at least 50-fold stronger than the affinity with which the compound binds to an α1-adrenergic receptor, and (c) exhibit 5-HT1A receptor antagonist activity on both pre-synaptic and post-synaptic 5-HT1A receptors, and their stereoisomers, hydrates, solvates and pharmaceutically acceptable salts are useful for the treatment of lower urinary tract disorders in mammals.